Goodwin Procter and Skadden, Arps, Slate, Meagher & Flom are aiding the deal that allows Novo Nordisk A/S to respond to demand for the drugs Wegovy and Ozempic.
Goodwin Procter is advising Novo Nordisk’s largest shareholder, Novo Holdings. Skadden is assisting Catalent Inc., a drug manufacturing company that Novo Holdings is buying for $16.5 billion. Jones Day is advising Catalent’s board.
The Goodwin team was led by partners Matt Mauney, Josh Zachariah, Kirkie Maswoswe, Rachel Frankeny and Andrew Kimball.
The Skadden team includes partners Todd Freed, Patrick Lewis, Richard Grossman, Page Griffin and Maria Raptis. Skadden also advised Catalent in its settlement with affiliates of activist investor Elliott Investment Management, which backs the sale to Novo.
The deal comes as producers juggle to keep up with increasing demand for diabetes and obesity drugs Wegovy and Ozempic. The acquisition is intended to increase Novo Nordisk’s capacity.
The deal is expected to close near the end of the year, subject to regulatory and shareholder approvals, the firms said.
To contact the reporter on this story:
To contact the editors responsible for this story:
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.